at Zacks.com (Wed, 12:00PM)
Citigroup likes what it sees in Novartis' (NVS +3.6%) today, upgrading the European drug giant to Buy on the back of a solid quarter and significant management changes. Citi says the departure of Dr. Vasella could lead to shareholder friendly activity, including; a streamlining of the company's group structure, monetization of its Roche (RHHBY.PK stake and a possible re-initiation of its buyback program.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 3:46AM)
at Investor's Business Daily (Mon, 8:02AM)
at Zacks.com (Jan 23, 2015)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs